In cancer treatment, contrast-enhanced MRI is useful for identifying the size and location of tumor masses. However, contrast-enhanced MRI does not lead to the diagnosis of tumor masses. Therefore, early blood tests and tumor biopsy results are important for differential diagnosis and early treatment decisions.

7 days ago

Journal

IL2 (Interleukin 2)

daunorubicin

Tirabrutinib-anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance. (PubMed, Expert Opin Drug Metab Toxicol)

Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways. However, Chou - Talalay analysis highlights the importance of appropriate dosing to achieve therapeutic synergy in combination regimens.

9 days ago

Journal

AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)

daunorubicin • Velexbru (tirabrutinib)

12d

Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells. (PubMed, Sci Rep)

In conclusion, these alkaloids enhanced the sensitivity of EPG85.257RDB and A2780 cells to daunorubicin, likely through inhibition of drug efflux activity. These findings highlight β-carboline alkaloids as promising candidates for combination therapy in overcoming multidrug resistance in cancer.

12 days ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1)

daunorubicin

17d

AML-DS-2025: The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia (clinicaltrials.gov)

P3, N=100, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

17 days ago

New P3 trial

GATA1 (GATA Binding Protein 1)

cytarabine • etoposide IV • daunorubicin • idarubicin hydrochloride

18d

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML (clinicaltrials.gov)

P2, N=240, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting

18 days ago

Enrollment open

Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • idarubicin hydrochloride • mitoxantrone

21d

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=102, Not yet recruiting, OHSU Knight Cancer Institute

21 days ago

New P2 trial

Venclexta (venetoclax) • cytarabine • daunorubicin • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)

21d

P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)

P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026

21 days ago

Trial completion date

ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK positive • TNFRSF8 positive • ALK negative

doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin

22d

CircRAD18 Regulates Daunorubicin Resistance in Acute Myeloid Leukemia Cells through MiR-185-5p/HDGF Axis (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)

Knocking down CircRAD18 can reduce HDGF expression by up-regulating miR-185-5p, thereby weakening DNR resistance in AML cells, inhibiting KG1a cell proliferation under DNR treatment, and promoting apoptosis.

22 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • miR-185 (MicroRNA 185) • HDGF (Heparin Binding Growth Factor)

daunorubicin

23d

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (clinicaltrials.gov)

P2, N=22, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2030 --> Sep 2029

23 days ago

Trial completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3 mutation

cytarabine • etoposide IV • midostaurin • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV

24d

Construction of genetically encoded biosensors for monitoring cytosolic and mitochondrial H2O2 in response to nanozymes in THP-1 cells. (PubMed, Biophys Rep)

Using this biosensor, we examined the dynamics of cytosolic and mitochondrial H2O2 in response to Daunorubicin, Fe3O4 nanozyme with Polyetherimide (PEI)- or Dextran (Dex)-modification, and Prussian blue nanozyme with different diameters. Results indicated that the particle size of PBNPs and surface modification of Fe3O4 play critical roles in their intracellular effects on the aspect of H2O2 modulation. The live-cell biosensors thus provide a powerful tool for detecting the variations of cytosolic and mitochondrial H2O2 in response to nanozymes, thereby facilitating a better understanding of the biological effects of nanozymes and their potential biomedical applications.

24 days ago

Journal

CAT (Catalase)

daunorubicin

24d

CR109124: A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (clinicaltrials.gov)

P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2024 --> Oct 2026

24 days ago

Trial primary completion date

NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)

Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)